McDermott Will & Schulte Advises Amulet Capital Partners on Acquisition of TFP Fertility Group

Key Takeaways

• Amulet acquires TFP Fertility Group from Benefit Street Partners
• Deal announced May 7; financial terms undisclosed
• Acquisition expands Amulet’s portfolio in UK/Northern Europe fertility market
• McDermott’s healthcare PE team led transaction across multiple jurisdictions
• Focus on patient access, experience, and market leadership

Pulse Analysis

Fertility care is emerging as one of the fastest‑growing segments of the healthcare industry, driven by delayed family planning, advances in assisted reproductive technology, and supportive public policies in the UK and Northern Europe. Private‑equity firms have been accelerating investments in this space, attracted by recurring revenue models and the potential for consolidation among fragmented clinics. The acquisition of TFP Fertility Group reflects this trend, positioning Amulet to capture market share in a region where demand outpaces supply and regulatory frameworks are increasingly harmonized across borders.

Amulet Capital Partners has built its reputation on backing providers that deliver high‑quality, patient‑centered care. By adding TFP’s network of clinics, Amulet can leverage economies of scale to expand access, streamline operations, and introduce digital health tools that improve the patient journey. The firm’s strategy emphasizes not only financial returns but also measurable improvements in outcomes and experience, aligning with broader industry moves toward value‑based care. As fertility demand rises, Amulet’s investment is poised to accelerate service expansion into underserved areas while strengthening TFP’s position as a market leader.

Complex cross‑border transactions in healthcare require deep legal expertise to manage regulatory compliance, data‑privacy obligations, and financing structures. McDermott Will & Schulte’s dedicated healthcare private‑equity practice, staffed by more than 150 lawyers worldwide, provides the necessary infrastructure to navigate these challenges. Their involvement ensures that the deal adheres to both UK and EU regulations while facilitating efficient deal execution. This collaboration illustrates how specialized law firms are becoming integral partners for private‑equity sponsors seeking to scale healthcare assets across multiple jurisdictions.